Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | UGCG | Q16739 | 2/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126800 | 0.93 | TSHR (0.38) | SPHK1SPHK2TSHRGBA1UGCG | |
| SCHEMBL131035 | 0.91 | SPHK1 (0.40) | SPHK1SPHK2TSHRGBA1UGCG | |
| SCHEMBL128798 | 0.90 | — | — | |
| SCHEMBL129491 | 0.88 | — | — | |
| SCHEMBL7298656 | 0.84 | NAAA (0.33) | SPHK1SPHK2GBA1UGCGGBA2 | |
| SCHEMBL126794 | 0.83 | TSHR (0.41) | SPHK1SPHK2TSHRGBA1UGCG | |
| SCHEMBL7303667 | 0.81 | SPHK2 (0.35) | SPHK1SPHK2TSHRGBA1UGCG | |
| SCHEMBL128161 | 0.81 | TSHR (0.39) | SPHK1SPHK2TSHRGBA1UGCG | |
| SCHEMBL6305480 | 0.81 | SPHK1 (0.38) | SPHK1SPHK2GBA1UGCGGBA2 | |
| SCHEMBL126364 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | SPHK1 772/4885SPHK2 730/4885TSHR 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.